Why: Depression is common in late life, effecting nearly five million of the 31 million Americans aged 65 and older. Both major and minor depression are reported in 13% of community dwelling older ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

A study published in Journal of American Geriatrics Society on Wednesday finds that older adults face lower odds for depression if they didn’t have depression earlier in life or had higher income ...

Older adults who had a negative history of depression or had ... The Patient-Reported Outcomes Measurement Information System (PROMIS®) depression scale was used to determine the depression status.

Having depression is known to increase a person's risk of developing dementia, but depression is also an early indicator of ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.